This study introduces an explainable deep radiogenomic framework for non-invasively predicting MGMT promoter methylation status in glioblastoma using multi-parametric MRI. By fusing radiomic features with deep learning and providing explainable AI insights, the method offers a robust and interpretable approach to a crucial biomarker for treatment response.